Review
Immunology
Amirhossein Ghaseminejad-Raeini, Ali Ghaderi, Amirmohammad Sharafi, Behrad Nematollahi-Sani, Maryam Moossavi, Afshin Derakhshani, Gholamreza Anani Sarab
Summary: For many years, vitamin D has been known for its role in maintaining calcium and phosphate balance, but recent research has focused on its immunomodulatory role, which has generated conflicting results. The presence of vitamin D receptors in various immune cell types has allowed for the investigation of its precise role in diseases, specifically autoimmune disorders. Physiologically activated vitamin D not only modulates innate and acquired immune cell responses, but also promotes a tolerogenic immune state. Recent studies suggest that this important micronutrient plays a complex role in immune system pathways and associated disorders. Understanding this field is still relatively new, and some studies indicate that patients with severe autoimmune illnesses often have vitamin D deficiencies. This review aims to provide a clear understanding of the latest research on the immune system-related roles of vitamin D, including the pathophysiology of major disorders.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Antoine N. Kraemer, Anna-Lena Schaefer, Dalina T. L. Sprenger, Bettina Sehnert, Johanna P. Williams, Aileen Luo, Laura Riechert, Qusai Al-Kayyal, Helene Dumortier, Jean-Daniel Fauny, Zoltan Winter, Kathrin Heim, Maike Hofmann, Martin Herrmann, Guido Heine, Reinhard E. Voll, Nina Chevalier
Summary: Vitamin D deficiency is highly prevalent worldwide and is associated with the development of systemic lupus erythematosus (SLE) and other immune-mediated diseases. In this study, low vitamin D intake was found to accelerate lupus progression in lupus-prone mice, possibly by affecting the regulatory phenotype of lymphocytes. Correcting vitamin D deficiency can not only prevent osteoporosis but also serve as an important component in the prevention and treatment of lupus and other immune-mediated diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Nutrition & Dietetics
Artur Mazur, Paulina Fraczek, Jacek Tabarkiewicz
Summary: Epigenetics regulates gene expression without changing the DNA sequence through mechanisms such as DNA methylation, histone modifications, and profiling of non-coding RNA. Disruptions in the balance of these mechanisms can increase the risk of disease. Diet and nutrition, including sufficient vitamin D, play a significant role in epigenetic modeling and may impact the course of autoimmune disorders.
Article
Immunology
Cristian R. Falcon, Nicolas Fernandez Hurst, Ana Laura Vivinetto, Pablo Hector Horacio Lopez, Adolfo Zurita, Gerardo Gatti, Laura Cervi, Clara G. Monferran, German A. Roth
Summary: DZ has immunomodulatory effects by reducing pro-inflammatory cytokine secretion and shifting immune responses towards an anti-inflammatory profile. It can be used preventively to treat experimental autoimmune encephalomyelitis (EAE) and therapeutically to ameliorate clinical signs and prevent axonal damage.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Dirk Lemke, Rainer Johannes Klement, Felix Schweiger, Beatrix Schweiger, Jorg Spitz
Summary: Vitamin D-3 plays an important role in treating autoimmune diseases, and high-dose vitamin D-3 therapy can improve treatment outcomes. Acquired vitamin D resistance may be a plausible pathomechanism for the development of autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Yuqian Liu, Meng Tang, Qin Zhang, Cuican Li, Rundong Lv, Hanhui Min, Xiaohui Zhou
Summary: The research found that in the experimental autoimmune prostatitis model, significant relief of pelvic pain and prostatitis symptoms can be achieved by injecting anti-T2 polyclonal antibodies, indicating that T2 may be an important factor in the disease and contribute to a better understanding of the etiology of chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS).
Article
Pharmacology & Pharmacy
Nicholas Dopkins, William Becker, Kathryn Miranda, Mike Walla, Prakash Nagarkatti, Mitzi Nagarkatti
Summary: Tryptamine, a microbiota-derived AHR agonist, attenuates symptoms of experimental autoimmune encephalomyelitis (EAE) by reducing inflammation cell infiltration and increasing regulatory T cells, while also altering gut microbiota and promoting butyrate production.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Alessio Gerussi, Ambra Natalini, Fabrizio Antonangeli, Clara Mancuso, Elisa Agostinetto, Donatella Barisani, Francesca Di Rosa, Raul Andrade, Pietro Invernizzi
Summary: Drug-induced liver injury (DILI) is a challenging clinical event with various phenotypes and limited diagnostic and therapeutic tools. Recent advancements in genomics and immunology offer insights into the molecular aspects of DILI, helping to improve understanding and research in this field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Daniela Gallo, Denisa Baci, Natasa Kustrimovic, Nicola Lanzo, Bohdan Patera, Maria Laura Tanda, Eliana Piantanida, Lorenzo Mortara
Summary: Vitamin D plays a vital role in bone health and is involved in various cellular processes. It has been found to have clinical implications in immune surveillance against infections and autoimmune/inflammatory diseases. Recent research has focused on the role of innate immune cells and their interaction with vitamin D and acquired immune cells in the onset and regulation of certain autoimmune diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Rui Zhao, Wei Zhang, Chenghong Ma, Yaping Zhao, Rong Xiong, Hanmin Wang, Weiwen Chen, Song Guo Zheng
Summary: Vitamin D is essential for human health, playing a critical role in calcium and phosphorus metabolism, bone health, and the immune system. Research has shown a close connection between vitamin D deficiency and autoimmune thyroid diseases, highlighting the importance of understanding its mechanisms and implications for intervention and treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Nutrition & Dietetics
Filip Lebiedzinski, Katarzyna Aleksandra Lisowska
Summary: Hashimoto's thyroiditis (HT) is an autoimmune disease affecting the thyroid gland and often requires lifelong treatment. Vitamin D deficiency is associated with a higher prevalence of thyroid autoimmunity, and vitamin D supplementation shows promise in reducing antibody levels and improving thyroid function in HT patients. Studies suggest that vitamin D may impact various immune mechanisms and improve clinical outcomes, but further research is needed.
Article
Nutrition & Dietetics
Maja Cvek, Dean Kalicanin, Ana Baric, Marko Vuletic, Ivana Gunjaca, Vesela Torlak Lovric, Veselin Skrabic, Ante Punda, Vesna Boraska Perica
Summary: Our study found no significant association between vitamin D and HT, but there may be a slight decrease in vitamin D levels associated with overt hypothyroidism. A significant correlation was identified between vitamin D and TSH in all HT patients, as well as a correlation between vitamin D and systolic blood pressure in OVERT HT patients.
Editorial Material
Immunology
Endrit Shahini, Francesco Pesce, Antonella Argentiero, Antonio Giovanni Solimando
Summary: Vitamin D deficiency may be associated with increased severity of respiratory distress in COVID-19 infection, with potential effects on the immunogenicity of SARS-CoV-2 vaccines. Vitamin D supplementation could help reduce infection risk and improve immune function.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Maud Bagnoud, Jana Remlinger, Marine Massy, Dmitri Lodygin, Anke Salmen, Andrew Chan, Fred Luehder, Robert Hoepner
Summary: This study reveals the interaction between glucocorticoid receptor (GR) and vitamin D receptor (VDR) in the therapeutic effects of vitamin D (VitD) on experimental autoimmune encephalomyelitis (EAE) disease severity. The results demonstrate that the presence of GR in T cells is necessary for VDR to appropriately signal and mediate the therapeutic effects of VitD.
Article
Pharmacology & Pharmacy
Peng Wang, Qian Wu, Zong-Wen Shuai
Summary: Ficolins are pattern-recognition molecules that can trigger complement activation and play a crucial role in various autoimmune diseases. Studies have elucidated the immunological regulations of ficolins and discussed their potential diagnostic and therapeutic applications in autoimmune diseases.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
Athena Philis-Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell-Jones, Julio Rosenstock
Summary: This article describes the clinical development program ONWARDS phase 3a, which investigates the use of once-weekly basal insulin icodec in the treatment of type 2 and type 1 diabetes. Six trials are being conducted to evaluate the efficacy and safety of icodec, with consideration of different clinical scenarios and comparator treatments.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Caro Minschart, Astrid Lammertyn, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van Den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima
Summary: The level of gestational weight gain (GWG) during pregnancy is associated with adverse pregnancy outcomes in women with gestational diabetes (GDM) compared to women with normal glucose tolerance (NGT). Low GWG below recommended levels frequently occurs in GDM women without increased risk for adverse outcomes. Excessive GWG is associated with increased risk for neonatal hypoglycemia and worse metabolic profile postpartum in GDM women, and with higher rates of instrumental delivery and larger infants in NGT women.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Editorial Material
Endocrinology & Metabolism
Alice Y. Y. Cheng, Marilia Brito Gomes, Sanjay Kalra, Andre-Pascal Kengne, Chantal Mathieu, Jonathan E. Shaw
Summary: In 2022, the WHO established the first global targets for diabetes mellitus. These targets aim to achieve, by 2030, that 80% of people with diabetes mellitus are diagnosed, 80% of those with diabetes mellitus have good control of blood sugar and blood pressure, 60% of those over 40 receive statin treatment, and 100% of those with type 1 diabetes mellitus have access to affordable insulin and blood glucose monitoring.
NATURE REVIEWS ENDOCRINOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Andrea M. Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A. Hashim, David Kerr, Rodica Pop-Busui, Connie M. Rhee, Viral N. Shah, Lia Bally, Antoni Bayes-Genis, Yong Mong Bee, Richard Bergenstal, Javed Butler, G. Alexander Fleming, Gregory Gilbert, Stephen J. Greene, Mikhail N. Kosiborod, Lawrence A. Leiter, Boris Mankovsky, Thomas W. Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw Patel, Anne Peters, Eun-Jung Rhee, Giuseppe M. C. Rosano, David B. Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo Umpierrez, Kayo Waki, Eugene E. Wright Jr, Alan H. B. Wu, David C. Klonoff
Summary: The Diabetes Technology Society assembled a panel of clinician experts to review the current evidence on biomarker screening of people with diabetes for heart failure and provide recommendations for diagnosis and management to prevent disease progression.
PROGRESS IN CARDIOVASCULAR DISEASES
(2023)
Article
Obstetrics & Gynecology
Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Katrien Benhalima
Summary: This study aims to evaluate the efficacy, safety and cost-effectiveness of the MiniMed (TM) 780G HCL system in pregnant women with T1D. It is an international, open-label, randomized controlled trial that will compare the MiniMed (TM) 780G HCL system to standard of care. The primary outcome is the time spent within the pregnancy glucose target range.
BMC PREGNANCY AND CHILDBIRTH
(2023)
Review
Endocrinology & Metabolism
Katrien Benhalima, Kaat Beunen, Sarah E. Siegelaar, Rebecca Painter, Helen R. Murphy, Denice S. Feig, Lois E. Donovan, Sarit Polsky, Elizabeth Buschur, Carol J. Levy, Yogish C. Kudva, Tadej Battelino, Lene Ringholm, Elisabeth R. Mathiesen, Chantal Mathieu
Summary: Maintaining glucose concentrations within target, appropriate gestational weight gain, lifestyle management, and using antihypertensive treatment and low-dose aspirin if necessary can reduce the risk of complications in pregnancies complicated by type 1 diabetes. Hybrid closed-loop insulin delivery systems show promise as a treatment option during pregnancy.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill
Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
Chantal Mathieu, Alice Wiedeman, Karen Cerosaletti, S. Alice Long, Elisavet Serti, Laura Cooney, Joan Vermeiren, Silvia Caluwaerts, Karolien Van Huynegem, Lothar Steidler, Sven Blomme, Pieter Rottiers, Gerald T. Nepom, Kevan C. Herold
Summary: The oral delivery of AG019 was found to be well tolerated and safe as a monotherapy and in combination with teplizumab in patients with type 1 diabetes. The treatment did not interfere with the safety profile of teplizumab and may have additional biological effects, including changes in preproinsulin-specific T cells. Preliminary data support further studies with AG019 alone or in combination with teplizumab or other systemic immunotherapies for type 1 diabetes.
Review
Endocrinology & Metabolism
Chantal Mathieu, Iraj Ahmadzai
Summary: This review examines the use of GLP-1 receptor agonists, specifically in type 1 diabetes, and concludes that they can lower weight and required insulin doses. However, their effects on glucose control and hypoglycemia vary depending on study protocols. Side effects include gastrointestinal complaints. The potential use of GLP-1 receptor agonists in other forms of diabetes is briefly discussed, but current evidence is limited.
Article
Endocrinology & Metabolism
Robert Moulder, Tommi Valikangas, M. Karoliina Hirvonen, Tomi A. Suomi, Caroline A. Brorsson, Niina Lietzen, Sylvaine F. A. Bruggraber, Lut Overbergh, David B. Dunger, Mark Peakman, Piotr J. Chmura, Soren Brunak, Anke M. Schulte, Chantal Mathieu, Mikael Knip, Laura L. Elo, Riitta Lahesmaa
Summary: There is a growing need for markers that could indicate the decline in beta cell function in type 1 diabetes. This study evaluated a panel of proteins in serum from newly diagnosed individuals and found associations between certain proteins and beta cell function. The findings suggest that these proteins may be useful in future studies of beta cell function in type 1 diabetes.
Editorial Material
Endocrinology & Metabolism
Mark A. Atkinson, Michael J. Haller, Desmond A. Schatz, Manuela Battaglia, Chantal Mathieu
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Paul W. Franks, William T. Cefalu, John Dennis, Jose C. Florez, Chantal Mathieu, Robert W. Morton, Martin Ridderstrale, Henrik H. Sillesen, Coen D. A. Stehouwer
Summary: Cardiometabolic disease poses a major threat to global health. Precision medicine has the potential to reduce the burden of this disease cluster and improve evidence-based medicine. It requires a well functioning system involving various stakeholders and relies on powerful computing infrastructure and research methods for analysis of large-scale data.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Meeting Abstract
Endocrinology & Metabolism
S. Charleer, S. Fieuws, T. Boone, C. De Block, N. Bolsens, F. Nobels, K. Mikkelsen, C. Mathieu, P. Gillard
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Meeting Abstract
Endocrinology & Metabolism
S. Charleer, C. De Block, N. Bolsens, L. Van Huffel, F. Nobels, C. Mathieu, P. Gillard
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Meeting Abstract
Endocrinology & Metabolism
C. Mathieu
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Shane Kelly, Katherine J. L. Jackson, Timothy J. Peters, Dan Suan, Christopher C. Goodnow
Summary: This study successfully identified and characterized PR3-specific B cells from the peripheral blood of patients with PR3 autoantibodies. These cells exhibited specific immunological features, suggesting that PR3 self-reactivity may occur early in B-cell development.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Ana Merino-Vico, Jan Piet van Hamburg, Paul Tuijnenburg, Giulia Frazzei, Aram Al-Soudi, Carlo G. Bonasia, Boy Helder, Abraham Rutgers, Wayel H. Abdulahad, Coen A. Stegeman, Jan-Stephan Sanders, Laura Bergamaschi, Paul A. Lyons, Theo Bijma, Laura van Keep, Kirsten Wesenhagen, Aldo Jongejan, Henric Olsson, Niek de Vries, Taco W. Kuijpers, Peter Heeringa, Sander W. Tas
Summary: B lineage cells play a critical role in ANCA-associated vasculitis (AAV), and the transcription factor NF-kappa B may be a potential therapeutic target for AAV and other autoimmune diseases with prominent B cell involvement.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Christopher Nelke, Thomas Muentefering, Derya Cengiz, Lukas Theissen, Vera Dobelmann, Christina B. Schroeter, Helena Block, Corinna Preu, Alexander P. E. Michels, Stefanie Lichtenberg, Marc Pawlitzki, Steffen Pfeuffer, Niklas Huntemann, Alexander Zarbock, Thorben Briese, Christoph Kittl, Carsten Dittmayer, Thomas Budde, Ingrid E. Lundberg, Werner Stenzel, Sven G. Meuth, Tobias Ruck
Summary: K2P2.1 plays a regulatory role in the autoimmune response of idiopathic inflammatory myopathies (IIMs), by regulating inflammatory cell response, adhesion, and transmigration in both endothelial and skeletal muscle cells. Inhibiting K2P2.1 enhances the inflammatory response, while activating K2P2.1 improves the disease course.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Xuan Zhang, Jun Xia, Ying Jiang, David S. Pisetsky, Josef S. Smolen, Rong Mu, Shengming Dai, Michael E. Weinblatt, Tore K. Kvien, Juan Li, Thomas Doerner, Yu Zhang, Liwei Lu, Chengde Yang, Pingting Yang, Yuan Zhang, Chenchen Xu, Zhan Zhao, Peter E. Lipsky
Summary: The study suggests that TwHF may be as effective as MTX in treating active RA, and combination therapy may be more effective than monotherapy.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, Zihao Zheng, Alex M. Robbins, S. Janna Bashar, Michael F. Denny, Sara S. Mccoy, Irene M. Ong, Miriam A. Shelef
Summary: Rheumatoid factors (RFs) are polyreactive antibodies that can bind disease-specific epitopes. Recent studies have found that RFs in COVID-19 can bind novel IgG epitopes, which provides new insights into the mechanism of RFs.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Johanne Liberatore, Yann Nguyen, Jerome Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puechal, Loic Guillevin, Benjamin Terrier
Summary: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) can lead to decreased gammaglobulin levels, which is associated with an increased risk of relapse and severe infections. Older age, low gammaglobulin levels, and receiving pulses of methylprednisolone at induction therapy are risk factors for gammaglobulin decline.
JOURNAL OF AUTOIMMUNITY
(2024)